Liraglutide Effect and Action in Diabetes (LEAD-1): Effect on Glycaemic Control After Once Daily Administration of Liraglutide in Combination With Glimepiride Versus Glimepiride Monotherapy Versus Glimepiride and Rosiglitazone Combination Therapy in Subjects With Type 2 Diabetes.
Phase of Trial: Phase III
Latest Information Update: 02 Feb 2017
At a glance
- Drugs Liraglutide (Primary) ; Glimepiride; Rosiglitazone
- Indications Obesity; Type 2 diabetes mellitus
- Focus Pharmacodynamics; Registrational; Therapeutic Use
- Acronyms LEAD-1
- Sponsors Novo Nordisk
- 07 Jun 2017 Biomarkers information updated
- 09 Jul 2012 Additional trial location (New Zealand) added as reported by ClinicalTrials.gov.
- 25 Jun 2010 Outcomes from a pooled anlaysis of the 6 LEAD trials were reported at the 70th Annual Scientific Sessions of the American Diabetes Association.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History